Needham & Company LLC reaffirmed their hold rating on shares of ZimVie (NASDAQ:ZIMV - Free Report) in a research report report published on Thursday morning, Benzinga reports.
Several other analysts have also recently commented on the company. Barclays upped their target price on ZimVie from $13.00 to $16.00 and gave the company an underweight rating in a report on Tuesday, March 5th. JPMorgan Chase & Co. boosted their price target on ZimVie from $10.00 to $16.00 and gave the company a neutral rating in a research note on Wednesday, December 20th.
Get Our Latest Report on ZIMV
ZimVie Price Performance
ZIMV stock traded down $0.10 during midday trading on Thursday, reaching $16.94. The company had a trading volume of 229,660 shares, compared to its average volume of 364,699. The company has a market capitalization of $461.11 million, a price-to-earnings ratio of -1.14 and a beta of 2.18. The stock has a 50 day moving average price of $17.82 and a 200-day moving average price of $14.05. ZimVie has a 1-year low of $6.52 and a 1-year high of $20.91. The company has a debt-to-equity ratio of 1.26, a current ratio of 2.78 and a quick ratio of 2.32.
ZimVie (NASDAQ:ZIMV - Get Free Report) last posted its quarterly earnings results on Wednesday, February 28th. The company reported $0.10 EPS for the quarter. ZimVie had a positive return on equity of 2.44% and a negative net margin of 51.33%. The business had revenue of $113.07 million during the quarter.
Institutional Trading of ZimVie
A number of institutional investors have recently added to or reduced their stakes in the stock. Scarborough Advisors LLC bought a new position in ZimVie during the 4th quarter worth approximately $28,000. Tower Research Capital LLC TRC lifted its stake in shares of ZimVie by 388.7% in the 3rd quarter. Tower Research Capital LLC TRC now owns 3,245 shares of the company's stock valued at $31,000 after purchasing an additional 2,581 shares during the period. Natixis purchased a new position in ZimVie during the fourth quarter valued at $35,000. US Bancorp DE raised its stake in ZimVie by 276.6% during the fourth quarter. US Bancorp DE now owns 2,806 shares of the company's stock valued at $50,000 after buying an additional 2,061 shares during the last quarter. Finally, Royal Bank of Canada raised its stake in ZimVie by 44.0% during the second quarter. Royal Bank of Canada now owns 4,681 shares of the company's stock valued at $52,000 after buying an additional 1,430 shares during the last quarter. Hedge funds and other institutional investors own 95.63% of the company's stock.
About ZimVie
(
Get Free Report)
ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.
Further Reading
Before you consider ZimVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ZimVie wasn't on the list.
While ZimVie currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
